Quantum BioPharma Ltd. Files 6-K, Incorporates Press Release
Ticker: QNTM · Form: 6-K · Filed: Oct 21, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $700,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, registration-statement, press-release
Related Tickers: QNTB
TL;DR
Quantum BioPharma (QNTB) filed a 6-K on Oct 21, incorporating a press release into its F-3 registration statement.
AI Summary
Quantum BioPharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on October 21, 2024, incorporating by reference a press release issued on the same date. This filing is part of their Registration Statement on Form F-3 (SEC File No. 333-276264). The company is incorporated in Canada and its principal executive office is located in Toronto, Ontario.
Why It Matters
This filing indicates ongoing reporting activity and incorporation of recent news into SEC filings, which is relevant for investors tracking the company's disclosures.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that incorporates a press release and registration statement, not indicating new material events or financial distress.
Key Numbers
- 001-39152 — Commission File Number (Identifies the company's filing series with the SEC)
Key Players & Entities
- Quantum BioPharma Ltd. (company) — Registrant
- FSD Pharma Inc. (company) — Former company name
- October 21, 2024 (date) — Filing and press release date
- Form F-3 (document) — Registration statement type
- 333-276264 (document_id) — Registration statement file number
- Toronto, Ontario (location) — Principal executive office location
FAQ
What is the purpose of incorporating the press release into the Form F-3 Registration Statement?
The filing states that Exhibit 99.1 (the press release) is incorporated by reference into the Registrant's Registration Statement on Form F-3, meaning the information in the press release is now part of the official SEC filing for the registration statement.
When was Quantum BioPharma Ltd. formerly known as FSD Pharma Inc.?
The company changed its name from FSD Pharma Inc. on March 27, 2019.
What is the SIC code for Quantum BioPharma Ltd.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where are Quantum BioPharma Ltd.'s principal executive offices located?
The principal executive offices are located at 55 University Avenue, Suite 1003, Toronto, Ontario, M5L 2H7, Canada.
Does Quantum BioPharma Ltd. file annual reports under Form 20-F or 40-F?
Quantum BioPharma Ltd. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 252 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-10-21 08:50:38
Key Financial Figures
- $700,000,000 — nd Others, Seeking Damages In Excess Of $700,000,000 Usd, For Possible Stock Price Manipulat
Filing Documents
- fsd_6k.htm (6-K) — 12KB
- fsd_ex991.htm (EX-99.1) — 22KB
- fsd_ex991img1.jpg (GRAPHIC) — 8KB
- 0001654954-24-013137.txt ( ) — 46KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: October 21, 2024 By: /s/ Donal Carroll Donal Carroll, Chief Financial Officer 3 EXHIBIT INDEX Exhibit Description Exhibit 99.1 Press Release dated October 21, 2024 4